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Abstract
Keratinocyte growth factor (KGF, fibroblast growth factor-7) is a fibroblast-derived mitogen, which stimulates proliferation
of epithelial cells. The expression of KGF by dermal fibroblasts is induced following injury and it promotes wound repair.
However, the role of KGF in cutaneous carcinogenesis and cancer progression is not known. We have examined the role of
KGF in progression of squamous cell carcinoma (SCC) of the skin. The expression of KGF receptor (KGFR) mRNA was lower in
cutaneous SCCs (n=6) than in normal skin samples (n=6). Expression of KGFR mRNA was detected in 6 out of 8 cutaneous
SCC cell lines and the levels were downregulated by 24-h treatment with KGF. KGF did not stimulate SCC cell proliferation,
but it reduced invasion of SCC cells through collagen. Gene expression profiling of three cutaneous SCC cell lines treated
with KGF for 24 h revealed a specific gene expression signature characterized by upregulation of a set of genes specifically
downregulated in SCC cells compared to normal epidermal keratinocytes, including genes with tumor suppressing
properties (SPRY4, DUSP4, DUSP6, LRIG1, PHLDA1). KGF also induced downregulation of a set of genes specifically
upregulated in SCC cells compared to normal keratinocytes, including genes associated with tumor progression (MMP13,
MATN2, CXCL10, and IGFBP3). Downregulation of MMP-13 and KGFR expression in SCC cells and HaCaT cells was mediated
via ERK1/2. Activation of ERK1/2 in HaCaT cells and tumorigenic Ha-ras-transformed HaCaT cells resulted in downregulation
of MMP-13 and KGFR expression. These results provide evidence, that KGF does not promote progression of cutaneous SCC,
but rather suppresses the malignant phenotype of cutaneous SCC cells by regulating the expression of several genes
differentially expressed in SCC cells, as compared to normal keratinocytes.
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Introduction
Keratinocyte growth factor (KGF, fibroblast growth factor-7
(FGF-7)) is produced by cells of mesenchymal origin and by
epidermal cd T cells [1,2]. KGF binds to a specific cell surface
receptor (KGFR), the splicing variant IIIb of FGF-receptor-2
(FGFR2-IIIb), which is expressed exclusively by various types of
epithelial cells [3]. KGF is mitogenic for epithelial cells and it
regulates epidermal morphogenesis, differentiation and homeosta-
sis [1,4–6]. In normal wound healing, the expression of KGF by
stromal fibroblasts is induced after injury in response to various
stimuli including transforming growth factor-a, interleukin-1, and
tumor necrosis factor-a [7–9]. The pivotal role of KGFR signaling
in wound repair was demonstrated by showing that expression of
dominant-negative form of KGFR in mouse epidermis results in
delayed wound closure [6]. In addition, the stimulatory effect of
KGF on cutaneous wound healing has been demonstrated by
delivery of exogenous KGF into wounds [10–12]. Recently, KGF
has also been recognized for its protective effect on normal
epithelial tissues, and use of recombinant KGF has been approved
for prevention and treatment of severe oral mucositis in patients
with hematologic cancers receiving high-dose chemotherapy and
radiation therapy followed by bone marrow transplantation.
However, the safety and efficacy of KGF for protecting normal
epithelial tissue in patients with non-hematologic malignancies
treated with chemo- and radiotherapy has not been established
and is under investigation [13–15].
Cutaneous squamous cell carcinoma (SCC) is the second most
common malignant tumor of skin, and its incidence is increasing
globally [16]. Chronic ulceration is a well recognized risk factor for
cutaneous SCC and ulceration is a typical clinical feature during
progression of UV-induced cutaneous SCC from intraepithelial
early lesion (actinic keratosis) to invasive and metastatic SCC [17].
Therefore, many characteristics of normal wound healing,
including proliferation of epidermal keratinocytes, inflammation,
and angiogenesis, are also typical features in cutaneous SCCs. The
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progression of epithelial cancers has been studied with variable
findings. The expression of KGF and KGFR correlates with
venous invasion of pancreatic cancer [18]. KGF and KGFR
expression is high in poorly differentiated lung adenocarcinoma
and in well differentiated lung SCC [19]. In esophageal cancer
KGFR expression correlates with differentiation, but the expres-
sion of KGF correlates with lymphatic invasion [20]. KGFR
expression is also associated with tumor suppression in bladder
carcinoma and prostate cancer [21–23]. Interestingly, prolifera-
tion of human head and neck SCC cell lines is not stimulated by
KGF [24]. KGF had no effect on the efficacy of chemotherapy on
KGFR positive head and neck SCC and colorectal cancer
xenografts [13]. In contrast, KGF was shown to counteract
anticancer treatment of breast cancer cell lines [15]. Thus,
depending on cancer type, KGF may exert tumor promoting or
suppressing effects or may not have any effect on cancer cell
behavior [13,15,23,24]. However, at present, the role of KGF in
the progression of cutaneous SCC is not known.
In the present study, we have examined the effect of KGF on
cutaneous SCC cells. The results show that although most SCC cell
lines express KGFR, KGF does not stimulate their proliferation.
Furthermore, the expression level of KGFR mRNA correlates
negatively with tumorigenic potential of Ha-ras-transformed
HaCaT cells. KGF reduces invasion capacity of KGFR-positive
cutaneous SCC cells and induces a specific gene expression
signature characterized by regulation of the expression of several
genes differentially expressed in SCC cells, as compared to normal
epidermal keratinocytes. Based on these findings, we propose that
KGF does not promote progression of cutaneous SCCs, but rather
suppresses the malignant phenotype of SCC cells.
Results
Expression of KGFR and KGF by cutaneous SCC tumor
cells
In order to elucidate the role of KGF in progression of
epidermal malignant tumors, we first determined the expression of
KGF and KGFR mRNA in cutaneous SCCs and in normal skin
by quantitative real-time RT-PCR (qPCR). The expression of
KGF mRNA in cutaneous SCCs (n=6) was detectable and
comparable to that in normal skin (n=6) (Figure 1A, upper panel).
The mean level of KGFR transcript expression was significantly
lower in cutaneous SCC tumors than in normal skin (Figure 1A,
lower panel).
Next, the expression of KGFR in cutaneous SCC cell lines,
normal primary epidermal keratinocytes, and in HaCaT cells, an
epidermal keratinocyte-derived non-tumorigenic cell line with p53
inactivation [25] was analyzed by RT-PCR. A specific 150 bp
fragment representing the specific IIIb-type exon of FGFR2-
receptor transcript was amplified from 4 out of 5 SCC cell lines
examined, from HaCaT cells, and from epidermal keratinocytes
(Figure 1B, upper panel). As expected, dermal fibroblasts were
negative for KGFR transcript.
The expression of KGFR by cutaneous SCC cells was further
determined by qPCR. KGFR mRNA was absent in 2 out of 8
cutaneous SCC cell lines and in 4 out of 8 SCC cell lines the level
of expression was comparable to normal epidermal keratinocytes
and HaCaT cells (Figure 1B, lower panel). Elevated levels of
KGFR transcript, as compared to normal keratinocytes, were
noted in 2 out of 8 SCC cell lines (Figure 1B, lower panel). KGF
mRNA was virtually absent in all 8 skin SCC cell lines examined
by qPCR, whereas it was expressed at high level by primary
dermal fibroblasts in culture (Figure 1C).
Lack of mitogenic response to KGF in cutaneous SCC
cells
To further examine the KGF response of cutaneous SCC cells,
two KGFR positive SCC cell lines, one primary (UT-SCC-12A)
and one metastatic (UT-SCC-7), as well as normal epidermal
keratinocytes and HaCaT cells were stimulated with various
concentrations of recombinant KGF for 20 h, and BrdU
incorporation was determined as a marker for DNA synthesis.
As shown in Figure 2A, KGF treatment enhanced DNA synthesis
of normal keratinocytes and HaCaT cells, but had no effect on the
SCC cell lines tested. Incubation with KGF for 48 h also increased
number of viable cells in keratinocyte and HaCaT cell cultures,
but not in two SCC cell line cultures (Figure 2B).
To examine the effect of fibroblast produced KGF on SCC
cells, normal human skin fibroblasts were transduced with
recombinant adenovirus encoding human KGF (RAdKGF), or
with empty control adenovirus (RAdpCA3), and cell culture
media were harvested 72 h later. High concentration of human
KGF was detected in medium of RAdKGF transduced
fibroblasts by Western blot analysis and ELISA (Figure 2C).
Serum starved SCC cells and HaCaT cells were cultured with
various concentrations (1–80%) of conditioned medium from
either RAdKGF or RAdpCA3 transduced fibroblasts for 26 h.
A concentration-dependent stimulation of DNA synthesis was
noted in HaCaT cells cultured with medium from RAdKGF
transduced fibroblasts, as compared to conditioned medium of
RAdpCA3 transduced dermal fibroblasts (Figure 2D). In
contrast, DNA synthesis of SCC cells was not stimulated by
medium from RAdKGF-transduced fibroblasts, and was even
reduced by highest concentrations of conditioned media
(Figure 2E,F).
KGF induces a specific gene expression signature in
cutaneous SCC cells
To further elucidate the effect of KGF on SCC cells, three
KGFR-positive cutaneous SCC cell lines were treated with KGF
for 24 h. Global gene expression profiling of KGF-treated SCC
cells, corresponding untreated control cells and untreated normal
keratinocytes was performed by oligonucleotide microarray
(Affymetrix). The expression of several genes involved in cell
growth, cellular signaling and regulation of cell cycle, as well as
extracellular and intracellular maintenance was clearly elevated in
KGF-treated skin SCC cell lines (Table 1). Five genes with tumor
suppressing properties, i.e. SPRY4 (Sprouty homolog 4) [26],
DUSP4 and DUSP6 (dual-specificity phosphatases 4 and 6) [27,28],
LRIG1 (Leucine-rich repeats and Ig-like domains 1) [29] and
PHLDA1 (Pleckstrin homology-like domain family A, member 1)
[30], were upregulated by KGF (1.5–2.1 fold) (Table 1).
Altogether 11 genes (including DUSP4, SPRY4, and ETV5), which
were specifically downregulated in SCC cell lines (more than 2-
fold) compared to normal keratinocytes were upregulated by KGF.
In contrast, five genes with elevated expression levels in SCC cell
lines compared to normal keratinocytes were further upregulated
by KGF (Table 1).
KGF treatment downregulated the expression of 18 genes in
cutaneous SCC cell lines. Interestingly, the expression of 13 of
these downregulated genes was at least 2-fold higher in
untreated SCC cells, as compared to normal epidermal
keratinocytes (Table 2). These genes included several antiviral
defense –related genes, genes encoding interferon-induced
proteins, and genes for growth regulation and signaling. Among
the most downregulated genes by KGF in SCC cells were four
genes specifically up-r e g u l a t e di nS C Cc e l l sc o m p a r e dt on o r m a l
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nase-3), MATN2 (matrilin 2), CXCL10 (chemokine (C-X-C
motif) ligand 10, IP-10), and IGFBP3 (insulin-like growth factor
binding protein 3).
Analysis of KGF regulated genes in SCC cells with Ingenuity
Pathway Analysis revealed functional relationship of several of
these genes with ERK1/2 signaling pathway, including DUSP6,
SPRY4, CXCL10, and MMP-13 (Figure 3).
The expression of matrilin 2, CXCL10, IGFBP3, DUSP4 and
DUSP6 is regulated by KGF in SCC cells
Due to their association with extracellular matrix (ECM)
homeostasis, regulation of angiogenesis and cancer progression
and metastasis [31–35], the expression of matrilin 2, CXCL10,
and IGFBP3 mRNA was further analyzed by qPCR in seven
cutaneous SCC cell lines, including one KGFR negative cell line
(UT-SCC-111), HaCaT cells and normal epidermal keratinocytes
Figure 1. Expression of KGF and KGFR mRNA in cutaneous SCC tumors and cell lines. (A) Cutaneous SCC tumor tissue samples (n=6) and
normal skin samples (n=6) were analyzed for KGF (upper panel) and KGFR (lower panel) mRNA levels by qPCR. The results were normalized for b-
actin mRNA levels in each sample. A dot represents the mean of duplicate analysis of one sample. Statistical analysis with independent samples T-test
(n.s., not significant). (B, upper panel) Human skin SCC cell lines (UT-SCC-7, -12A, -59A, -111, -118), HaCaT cells and normal epidermal keratinocytes
(NHEK PC, Kerat45B) were analyzed for the expression of KGFR mRNA using RT-PCR. RNA from normal human skin fibroblasts served as a negative
control. Amplification of a fragment of housekeeping gene GAPDH transcript was used as a loading control. (B, lower panel) KGFR mRNA expression
was quantified in human skin SCC cell lines (UT-SCC-7, -12A, -59A, -91A, -105, -111, -115, and -118), HaCaT cells and normal epidermal keratinocytes
(Kerat45B, Kerat63) with qPCR (n=3–4). (C) KGF mRNA expression was quantified in human skin SCC cell lines (UT-SCC-7, -12A, -59A, -91A, -105, -111,
-115, and -118), and normal human dermal fibroblasts with qPCR (n=3–4).
doi:10.1371/journal.pone.0033041.g001
KGF Regulation of Cutaneous SCC Cells
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33041treated with rKGF (10 ng/ml) for 24 h. As expected, the
expression of matrilin 2, CXCL10 and IGFBP3 mRNA was
undetectable or very low in normal keratinocytes (Figure 4A). In
accordance with the microarray data, the basal expression of
matrilin 2 mRNA was markedly elevated in all SCC cell lines, as
compared to normal keratinocytes, and was downregulated by
KGF in 5 out of 6 KGFR positive SCC cell lines (Figure 4A, upper
panel). CXCL10 mRNA expression was elevated in 3 out of 7
SCC cell lines compared to keratinocytes and KGF treatment
downregulated the expression significantly in 2 SCC cell lines
Figure 2. Lack of mitogenic response to KGF in skin SCC cells. (A) Growth supplement-starved normal primary keratinocytes (Kerat63),
serum-starved HaCaT cells and primary (UT-SCC-12A) and metastatic (UT-SCC-7) cutaneous SCC cells were treated with recombinant KGF (rKGF;
10 ng/ml) for 2 h followed by addition of BrdU. DNA-synthesis was determined as incorporation of BrdU into DNA after 18 h incubation. *p,0.02;
**p,0.005, with Mann-Whitney U-test, n=5–6. (B) Keratinocytes (Kerat63) (n=8), HaCaT cells (n=12), UT-SCC-12A (n=12) and UT-SCC-7 (n=12) cells
were treated as in (A). The relative amount of viable cells was determined using colorimetric assay of WST-1 reagent metabolism. *p,0.02;
**p,0.000001, with Mann-Whitney U-test. (C) Serum-starved primary human skin fibroblasts were infected with recombinant adenovirus (RAdKGF)
coding for human KGF, or with empty control adenovirus (RAdpCA3) (MOI 200) overnight and incubated in DMEM containing 0.5% FCS for 72 h. The
conditioned medium (c.m.) was analyzed for the presence of KGF by western blotting, and KGF concentration was quantified with ELISA. ProMMP-1
was visualized as control in c.m. by western blotting. (D–F) Serum-starved HaCaT cells (D), UT-SCC-12A cells (E) and UT-SCC-7 (F) cells were incubated
with c.m. in indicated concentrations or with rKGF for 18 h. BrdU was added and DNA-synthesis was analyzed after 8 h incubation. *
ap,0.05,
**
ap,0.01, *p,0.05 compared to 0% c.m., **p,0.02 compared to 0% c.m. with Mann-Whitney U-test, n=4–5.
doi:10.1371/journal.pone.0033041.g002
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detected in 6 out of 7 SCC cell lines, but not in normal
keratinocytes (Figure 4A, lower panel). Downregulation of
IGFBP3 mRNA levels by KGF was noted in 5 KGFR positive
cell lines. As expected, KGF had no effect on the expression of any
of the three genes in KGFR-negative cell line UT-SCC-111
(Figure 4A). In HaCaT cells the expression of matrilin 2,
CXCL10, and IGFBP3 was clearly elevated, as compared to
normal epidermal keratinocytes, and the expression of all three
genes was significantly downregulated by KGF (Figure 4A).
The regulation of DUSP4 and DUSP6 expression by KGF was
also verified by qPCR. The expression of DUSP4 mRNA was
markedly upregulated in 5 out of 6 KGFR positive SCC cell lines
and DUSP6 mRNA in all 6 KGFR positive SCC cell lines, as well
Table 1. Upregulation of different classes of genes in cutaneous SCC cells by KGF as determined by DNA microarray analysis.
Coded protein (Gene name) Ctrl rKGF
1 SCC/normal
2
ECM/ECM receptors, ECM modulators, cytoskeleton
Hyaluronan synthase 2 (HAS2)1 2 . 2 ,
Vimentin (VIM) 11 . 6 23.5
Leupaxin (LPXN) 11 . 7 ,
Adducin 2 (beta), transcript variant beta-4 (ADD2) 1 1.5 3.7
Micellaneous
Anthrax toxin receptor 2 (ANTXR2)1 2 . 2 22.3
Tissue factor pathway inhibitor 2 (TFPI2)1 2 . 0 23.4
Lung cancer metastasis-associated protein (MAG1, AGPAT9)1 1 . 9 ,
Homo sapiens hypothetical LOC390345 1 1.8 1.7
Arginase, type 2 (AGR2) 11 . 8 21.8
59-nucleotidase, ecto (CD73, NT5E)1 1 . 8 ,
Ankyrin repeat domain 22 (ANKRD22)1 1 . 8 23.4
Myeloma overexpressed (MYEOV) 1 1.7 2.1
SH3 domain and tetratricopeptide repeats 2 (SH3TC2)1 1 . 6 ,
Heparan sulfate glucosamine 3-O-sulfotransferase 1 (HS3ST1)1 1 . 6 ,
Ornithine decarboxylase 1 (ODC1)1 1 . 6 22.9
Discoidin, CUB and LCCL domain containing 2 (DCBLD2)1 1 . 6 ,
Semaphorin 3A (SEMA3A) 1 1.5 3.3
Carboxylesterase 1 (CES1) 11 . 5 22.0
ATP-binding cassette, sub-family A , member 13 (ABCA13) 1 1.5 2.6
Growth factors/ receptors/ signaling molecules/ transcription factors/ modulators
Dual specificity phosphatase 6 (DUSP6)1 2 . 1 ,
Ets variant gene 5 (ETV5) 12 . 0 22.1
Ets variant gene 4 (ETV4) 11 . 8 21.8
Heparin-binding EGF-like growth factor (HBEGF)1 1 . 8 21.5
Sprouty homolog 4 (SPRY4)1 1 . 7 22.7
G protein-coupled receptor kinase 5 (GRK5) 1 1.6 2.0
High mobility group AT-hook 2 (HMGA2)1 1 . 6 22.7
G protein-coupled receptor 153 (GPR153)1 1 . 6 ,
Dual specificity phosphatase 4 (DUSP4)1 1 . 6 25.4
Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1)1 1 . 5 ,
Follistatin, transcript variant FST317 (FST)1 1 . 5 ,
Forkhead box A2 (FOXA2) 11 . 5 ,
Cell cycle/ differentiation/ apoptosis
Immediate early response 3 (IER3)1 1 . 6 22.2
Tribbles homolog 2 (TRIB2) 11 . 6 ,
Pleckstrin homology-like domain, family A, member 1 (PHLDA1)1 1 . 5 ,
Three KGFR-positive SCC cell lines were serum-starved and treated with rKGF (10 ng/ml) for 24 h. Total RNA was analyzed for differential gene expression by Affymetrix
microarray. The genes with the hybridization signal above the median of the signal intensity distribution in at least one sample were analyzed. The genes with more
than 1.5 fold (150% of control) change in the expression level were included in the table.
1The data represents the fold-change of hybridization signal of KGF-treated cells over the untreated cells for the indicated gene.
2The data represents the fold-change of hybridization signal between untreated SCC cells and normal epidermal keratinocytes for the indicated gene. The negative fold-
change indicates decrease in hybridization signal in SCC cells compared to normal keratinocytes. , indicates positive or negative fold-change less than 1.5.
doi:10.1371/journal.pone.0033041.t001
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and DUSP6 expression was not altered by KGF in KGFR
negative SCC cell lines UT-SCC-91 and -111 (Figure 4B).
KGF downregulates the expression of MMP-13 and MMP-
7 and suppresses invasion of SCC cells
Matrix metalloproteinase-13 (MMP-13) is a wide spectrum
metalloendopeptidase implicated in invasion, vascularization,
and growth of cutaneous SCC [31,36]. In accordance with the
microarray data, the expression of MMP-13 transcript was
detected by qPCR in 5 out of 6 cutaneous SCC cell lines and
also in HaCaT cells (Figure 5A). KGF treatment potently and
significantly downregulated MMP-13 expression in all 5 SCC
cell lines and in HaCaT cells (by 47–94%), as compared to
corresponding untreated control cultures (Figure 5A). The
analysis of the conditioned media of three SCC cell lines and
HaCaT cells by western immunoblotting revealed a marked
reduction in MMP-13 production after KGF treatment, as
compared to corresponding untreated control cells (Figure 5B).
In contrast, production of MMP-2 in the same cultures was
unaltered by KGF.
MMP-7 has been identified as a marker for malignant
transformation of epidermal keratinocytes in cutaneous SCCs
[37,38]. Analysis by qPCR revealed expression of MMP-7
transcript in 4 out of 6 cutaneous SCC cell lines and in HaCaT
cells (Figure 5C) and KGF treatment resulted in a marked (34–
65%) reduction in MMP-7 mRNA expression compared to
untreated control cultures (Figure 5C). Furthermore, as shown in
Figure 5D, downregulation of MMP-13 and MMP-7 expression
by KGF was associated with reduction in invasion of UT-SCC-7
and -12A cells through collagen.
KGF-elicited downregulation of MMP-13 expression by
SCC cells is mediated via ERK1/2
KGF has been reported to activate extracellular signal-regulated
kinase 1/2 (ERK1/2) and p38 mitogen activated protein kinase
(MAPK) in epithelial cells [39–42]. In addition, pathway analysis
of genes regulated by KGF in SCC cells showed association of
several of these genes with ERK1/2 signaling (Figure 3). As shown
in Figure 6A and 6B, KGF induced rapid and persistent activation
of ERK1/2 in UT-SCC-7 cells and in HaCaT cells, noted 5 min
after addition of KGF and still persistent after 24 h (Figure 6A and
B). After 48 h, activation of ERK1/2 had returned to control level
in UT-SCC-7 cells, but was still prominent in HaCaT cells. In
UT-SCC-7 cells, activation of p38 was detected after 2 h and 24 h
and returned to control level in 48 h (Figure 6A). In HaCaT cells,
activation of p38 was most potent after 24- and 48-h KGF
treatment (Figure 6B). Rapid and transient activation of ERK1/2
Table 2. Downregulation of different classes of genes in cutaneous SCC cells by KGF as determined by DNA microarray analysis.
Coded protein (Gene name) Ctrl rKGF
1 SCC/normal
2
ECM/ECM receptors, ECM modulators, cytoskeleton
Matrix metallopeptidase 13 (MMP13) 1 23.0 79.0
Matrilin 2 (MATN2) 1 22.2 10.2
Growth factors/ receptors/ signaling molecules/ transcription factors/ modulators/ chemokines
Chemokine (C-X-C motif) ligand 10 (CXCL10)1 22.6 36.6
Tumor necrosis factor ligand superfamily member 10 (TNFSF10)1 22.5 7.3
Insulin-like growth factor binding protein 3 (IGFBP3)1 22.4 5.6
Signal transducer and activator of transcription 2 (STAT2)1 22.0 2.4
Antiviral defence/ interferon induced
Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1)1 22.5 2.6
Radical S-adenosyl methionine domain containing 2 (RSAD2)1 22.2 7.5
Myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse) (MX1)1 22.2 1.7
Tripartite motif-containing 22 (TRIM22) 1 22.2 ,
Guanylate binding protein 1, interferon-inducible (GBP1)1 22.1 3.1
Interferon-induced protein with tetratricopeptide repeats 2 (IFIT2)1 22.0 24.0
29,59-oligoadenylate synthetase 1, 40/46 kDa (OAS1)1 22.0 1.6
Micellaneous
Oxidized low density lipoprotein (lectin-like) receptor 1 (OLR1)1 22.8 12.7
Kynurenine 3-monooxygenase (KMO) 1 22.4 6.1
StAR-related lipid transfer protein 5 (STARD5)1 22.1 1.9
Serum amyloid A1 (SAA1) 1 22.0 ,
Solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 (SLC6A2)1 22.0 4.0
Three KGFR-positive SCC cell lines were serum-starved and treated with rKGF (10 ng/ml) for 24 h. Total RNA was analyzed for differential gene expression by Affymetrix
microarray. The genes with the hybridization signal above the median of the signal intensity distribution in at least one sample were analyzed. The genes with more
than 22.0 fold (less than 50% of control) change in the expression level were included in the table.
1The data represents the fold-change of hybridization signal of KGF-treated cells over the untreated control cells for the indicated gene. The negative fold-change
indicates decreased hybridization signal compared to control.
2The data represents the fold-change of hybridization signal between untreated SCC cells and normal epidermal keratinocytes for the indicated gene. , indicates
positive or negative fold-change less than 1.5.
doi:10.1371/journal.pone.0033041.t002
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the activation was less potent as in SCC and HaCaT cells
(Figure 6C).
To elucidate the role of ERK1/2 signaling pathway in
mediating downregulation of MMP-13 by KGF, SCC cells were
treated with PD98059, a small molecular inhibitor of ERK1/2
pathway. Parallel cultures were treated with SB203580, an
inhibitor of p38 MAPK. Co-treatment of cells with PD98059
resulted in potent inhibition of the downregulatory effect of KGF
on MMP-13 expression, whereas SB203580 potentiated the effect
Figure 3. Dynamic molecular network induced by KGF in skin SCC cells. KGF-treatment of skin SCC cells induces up- and downregulation of
variety of ERK1/2-regulated genes including upregulation of DUSP6, ETV5, SPRY1, and SPRY4 genes. KGF also induces downregulation of MMP7,
MMP13 and CXCL10. The data presented show KGF-induced changes as an average in three SCC cell lines. The image was generated using Ingenuity
Pathways Analysis (IPA). The symbols represent gene function, as indicated in legend on the right. Red color indicates gene upregulation and green
color downregulation by KGF. The genes with fold change .1.5 are indicated with the strongest red (up) and green (down) colors. The rainbow color
indicates a group of genes with up- or downregulation. Some of the groups (FGF, MMP, MKP1/3/4) are ‘‘opened’’ to show the regulation of individual
genes. The arrows and lines indicate direct (solid line) and indirect (dashed line) physical and functional interactions. The arrows show the direction of
regulation. The relations found in this study are highlighted with yellow arrows.
doi:10.1371/journal.pone.0033041.g003
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regulatory effect of KGF on MMP-13 expression in HaCaT cells
was abrogated by PD98059 and augmented by SB203580
(Figure 6E). PD98059 alone had no effect on MMP-13 expression
(Figure 6E). In accordance with previous observations [43],
SB203580 alone significantly inhibited the expression of MMP-
13 mRNA (Figure 6E). Abrogation of KGF-induced downregu-
lation of MMP-13 protein production by PD98059 in UT-SCC-7
cells was also evident, and SB203580 in combination with KGF
markedly reduced the production of MMP-13 (Figure 6F). MMP-1
expression was unaltered by KGF treatment or by small molecule
inhibitors (Figure 6F). The function of PD98059 and SB203580
was verified with immunoblotting for phospho-ERK1/2, and for
phospho-Creb, downstream target of p38, respectively (data not
shown).
Downregulation of KGFR (FGFR2-IIIb) expression after 24-h
treatment with KGF was also noted at protein level by western
immunoblotting of cell lysates of two SCC cell lines (Figure 6G).
Downregulation of KGFR mRNA by KGF in SCC and HaCaT
cells was also abrogated by PD98059 providing evidence for the
role of ERK1/2 signaling in the regulation of KGFR expression
(Figure 6H and 6I).
KGF downregulates MMP-13 and KGFR expression in Ha-
ras-transformed HaCaT cells via ERK1/2
To further corroborate the role of ERK1/2 signaling in the
downregulation of MMP-13 and KGFR in transformed epidermal
cells, we examined MMP-13 expression in three Ha-ras-trans-
formed HaCaT cell lines (A5, II4, and RT3), which represent an in
vitro model for different stages of cutaneous SCC tumor
progression. A5 is a benign tumorigenic cell line, II4 cells form
invasive malignant tumors, and RT3 forms metastatic tumors in
vivo [44,45]. As shown in Figure 7A, invasive II4 cells and
metastatic RT3 cells displayed more potent activation of ERK1/2,
as compared to benign tumorigenic A5 cells. Interestingly, the
expression level of MMP-13 mRNA correlated negatively with
ERK1/2 activation and the tumorigenic potential of the cell lines
(Figure 7B). In addition, the expression of KGFR mRNA
correlated negatively with the tumorigenic potential of Ha-ras-
HaCaT cells and their basal ERK1/2 activation (Figure 7C). KGF
significantly downregulated MMP-13 expression and PD98059
inhibited the downregulation in A5 and II4 cells, but not in the
metastatic cell line (RT3) which expressed KGFR and MMP-13
mRNA at very low level (Figure 7B,C). KGF also potently
downregulated KGFR mRNA expression in A5 and II4 cells and
Figure 4. The expression of matrilin 2, CXCL10, IGFBP3, DUSP4 and DUSP6 is regulated by KGF in cutaneous SCC cells. Cutaneous
SCC cell lines (UT-SCC-7, -12A, -59A, -91A, -105, -111, -115, and -118), HaCaT cells and normal keratinocytes (NHEK PC, Kerat45B) were serum starved,
treated with recombinant KGF (rKGF; 10 ng/ml) for 24 h and analyzed for (A) matrilin 2, CXCL10 and IGFBP3 mRNA and (B) DUSP4 and DUSP6 mRNA
expression with qPCR. The results were normalized for b-actin mRNA levels in each sample. Note that the cell lines UT-SCC-91A and UT-SCC-111 do
not express KGFR mRNA. *p,0.05, **p,0.01, ***p,0.001, with independent samples T-test, n=3–4.
doi:10.1371/journal.pone.0033041.g004
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induced downregulation of KGFR (Figure 7C).
Activation of ERK1/2 downregulates MMP-13 and KGFR
expression in HaCaT cells
To study the specific role of ERK1/2 pathway in the
downregulation of MMP-13 and KGFR expression, we used
adenoviral gene delivery (RAdMEK1CA) of constitutively active
MEK1 (the upstream kinase of ERK1/2) to obtain specific
activation of ERK1/2 (Figure 8A). As shown in Figures 8B and
8C, activation of ERK1/2 in HaCaT cells resulted in marked
reduction in MMP-13 and KGFR mRNA expression, as
compared to cells transduced with control adenovirus (RAdLacZ).
Together these results (Figures 7 and 8) provide evidence for the
involvement of ERK1/2 signaling in downregulation of MMP-13
and KGFR expression in SCC cells and show, that specific and
sustained ERK1/2 activation results in downregulation of MMP-
13 and KGFR expression.
Discussion
In this study we have examined the effect of KGF, a potent
epithelial cell mitogen, on cutaneous SCC cells. Our results show,
that most SCCs of skin in vivo express mRNAs for KGF and
KGFR, and that the level of KGFR expression is significantly
lower than in normal skin. The expression of KGFR was also
detected in the majority of primary and metastatic cutaneous SCC
cell lines, although 20% of the cell lines were negative for KGFR.
Interestingly, treatment of KGFR positive SCC cell lines with
recombinant KGF or by conditioned medium of human skin
fibroblasts overexpressing KGF after recombinant adenoviral
infection did not stimulate SCC cell proliferation indicating
altered response to KGF. In contrast, KGF clearly stimulated
proliferation of HaCaT cells and normal epidermal keratinocytes.
KGF treatment of cutaneous SCC cells induced a rapid and
persistent activation of ERK1/2, which was over by 48 h, whereas
in HaCaT cells ERK1/2 activation induced by KGF was more
persistent and persisted at least 48 h. In normal keratinocytes the
activation of ERK1/2 was rapid and transient. Thus, although
ERK1/2 was rapidly activated in both SCC cells and HaCaT cells
the results of the present study do not provide mechanistic
explanation for the difference between SCC cells and HaCaT cells
with respect to the mitogenic response to KGF. This difference
could be related to the magnitude and persistence of ERK1/2
activation by KGF, which appeared less prominent in SCC cells
compared to HaCaT cells. However, our results show, that in
cutaneous SCC cells, KGF induced activation of ERK1/2 does
not mediate mitogenic signaling, in contrast to HaCaT cells and
normal epidermal keratinocytes. As HaCaT cells, which harbor
inactivation of both p53 alleles represent an early step in the
Figure 5. KGF downregulates the expression of MMP-13 and MMP-7 and suppresses invasion of cutaneous SCC cells. (A, C)
Cutaneous SCC cell lines (UT-SCC-7, - 12A, -59A, -105, -111, and -118) and HaCaT cells were serum starved and treated with recombinant KGF (rKGF;
10 ng/ml). After 24-h treatment, total RNA was extracted and analyzed for the expression of MMP-13 (A) and MMP-7 (C) mRNA by qPCR. The results
were normalized for b-actin mRNA levels in the same samples. *p,0.05, **p,0.01, ***p,0.0001, with independent samples T-test, n=3–4. (B) HaCaT
cells and cutaneous SCC cells (UT-SCC-7, - 12A, and -118) were incubated with recombinant KGF (rKGF) for 72 h, and the medium samples were
analyzed for MMP-13 and MMP-2 protein using western immunoblotting. Each pair of control and KGF-treated sample contain equal amount of total
protein. (D) Cutaneous SCC cells (UT-SCC-7, -12A) (3610
5cells) treated with KGF (10 ng/ml) for 24 h were applied in collagen gel coated invasion
chamber and incubated for 48 h in the presence of KGF. The cells that had invaded through collagen matrix were stained, photographed and
counted. Statistical analysis with independent samples T-test, n=4–6.
doi:10.1371/journal.pone.0033041.g005
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PLoS ONE | www.plosone.org 10 March 2012 | Volume 7 | Issue 3 | e33041epidermal carcinogenesis, it is possible that KGF stimulates
proliferation of p53 negative keratinocytes in the UV-damaged
skin. However, as a result of malignant transformation, keratino-
cytes appear to lose the mitogenic response to KGF, and also
KGFR expression as will be discussed below. These observations
are in accordance with previous findings on lack of mitogenic
effect of KGF on head and neck SCC cells [24].
KGF was found to downregulate the expression of KGFR
mRNA in cutaneous SCC cells as well as in HaCaT cells
indicating functional negative feedback regulation of KGFR
signaling. It was also noted that in Ha-ras-transformed HaCaT
cell lines, activation of ERK1/2 negatively correlates with the
expression level of KGFR mRNA and inhibition of ERK1/2
signaling restores KGFR mRNA expression, demonstrating
ERK1/2 dependent negative regulation of KGFR expression.
Moreover, the expression level of KGFR decreased with the
increasing tumorigenic potential of Ha-ras-HaCaT cells. Thus, it is
likely, that the constitutive activation of ERK1/2 in a subset of the
invasive and metastatic cutaneous SCCs results in reduced
response to KGF via downregulation of KGFR expression. In
addition, skin SCC tumors showed reduced levels of KGFR
expression compared to normal skin in vivo, and a subset of
cutaneous SCC tumor cell lines were negative for KGFR.
Together these results suggest that the expression of KGFR is
downregulated and lost upon malignant transformation of
keratinocytes and during their progression to invasive and
metastatic cutaneous SCC cells. This is consistent with the reports
on the expression pattern of KGFR detected in esophageal,
bladder, and hepatocellular carcinoma [20,21,46].
Dissection of KGF response in skin SCC cells by microarray
based gene expression profiling and pathway analysis demonstrat-
ed upregulation of several known targets genes for ERK1/2
signaling, including ETV4 and ETV5, which code for Ets
transcription factors ETV4 and ETV5, respectively, and MAPK
phosphatases DUSP4 and DUSP6. DUSP6 is inducible by FGF
signaling, it is transcriptionally regulated by Ets protein, and it
specifically inactivates ERK1/2 [47,48]. Additional ERK1/2-
activated genes induced by KGF-treatment included IER3, which
has been shown to stimulate proliferation of HaCaT cells under
normal conditions, but sensitize them to stress-induced apoptosis
[49], proapoptotic PHLDA1 [30] and SPRY4 (Sprouty 4), which
belongs to a family of receptor tyrosine kinase inhibitors which can
inhibit ERK1/2 activation [50]. Of these, DUSP4 and DUSP6,
PHLDA1 and Sprouty 4 are characterized by tumor suppressing
properties [26–28,30]. Moreover, LRIG1, a gene coding for a
protein with recognized tumor suppressing properties, was
upregulated by KGF in SCC cells. LRIG1 plays a role in skin
homeostasis as a negative feedback regulator of EGF signaling by
inducing ubiquitination and degradation of EGFR [29]. Thus,
several genes that may play a role in the negative feedback
regulation of KGFR signaling were upregulated by KGF in
cutaneous SCC cells. In addition, induction of genes involved in
the regulation of ERK1/2 activity could also partially explain the
uncoupling of ERK1/2 activation from mitogenic signaling of
KGF response in SCC cells.
We also identified three novel KGF-regulated genes, MATN2,
CXCL10,a n dIGFBP3, which are upregulated in skin SCC cells in
comparison with epidermal keratinocytes and potently downregu-
lated by KGF.Matrilin 2 (MATN2) is a putative adaptor protein for
ECM assembly, which is widely expressed and localizes especially to
the basement membrane zones in skin and blood vessels in normal
and malignant tissues [51–53]. Chemokine CXCL10 is a ligand for
chemokine receptor CXCR3, and its expression is upregulated in
head and neck SCCs [54]. CXCL10 has been shown to promote
invasion-related properties of colorectal carcinoma cells [55], and it
also regulates angiogenesis [32]. IGFBP3 stabilizes insulin-like
growth factors (IGFs) affecting their affinity to IGF receptors, this
way serving as a negative regulator of cell proliferation and as a
promoter of apoptosis [33,56]. The expression of IGFBP3 is
upregulated in oral SCC tumors and cell lines [35] and in breast
cancer, in which the expression of IGFBP3 is associated with poor
outcome [57]. It is likely, that downregulation of the expression of
these genes in cutaneous SCC cells by KGF modulates biological
processes important in progression of cutaneous SCCs, such as cell
migration and proliferation, inflammation, angiogenesis and ECM
assembly.
MMP13 (collagenase-3) was identified as the most potently
downregulated gene by KGF in the cutaneous SCC cells. MMP-
13 is not expressed by normal epidermal keratinocytes in intact
skin or during wound repair, but it is readily expressed by tumor
cells in cutaneous SCCs [37,38,58]. MMP-13 can cleave a wide
range of ECM and non-matrix molecules [59] and it has been
implicated in invasion, growth, and vascularization of cutaneous
SCCs [31,36]. Our results also show, that KGF does not
downregulate MMP-13 expression, when activation of ERK1/2
is abolished by PD98059, indicating that ERK1/2-signaling is
required for KGF-induced downregulation of MMP-13 expres-
sion. This is in accordance with previous observation showing that
IFN-c reduces MMP-13 expression in cutaneous SCC cells in
ERK1/2-dependent manner [60]. In addition, constitutive
activation of ERK1/2 either by oncogenic Ha-ras or by
constitutively active MEK1 resulted in marked downregulation
of MMP-13 expression in epidermal keratinocyte-derived HaCaT
cells harboring p53 inactivation. This supports the hypothesis that
constitutive activation of ERK1/2 results in downregulation of
MMP-13 expression. It is also interesting to note that KGF
potently downregulates MMP-13 expression in non-tumorigenic
(HaCaT) and benign tumorigenic (A5) keratinocyte-derived cell
lines, which are phenotypically similar to epidermal keratinocytes
in UV-induced premalignant SCC precursor lesions (actinic
keratoses). These results suggest that KGF does not promote
progression of premalignant actinic keratoses to invasive SCCs.
Figure 6. KGF-elicited downregulation of MMP-13 and KGFR expression in cutaneous SCC and HaCaT cells is mediated via ERK1/2.
Serum-starved (A) skin SCC cells (UT-SCC-7), (B) HaCaT cells, and (C) human epidermal keratinocytes (NHEK-PC) were incubated with KGF (10 ng/ml)
for different periods of time, as indicated. Cell lysates were analyzed for phosphorylated forms of ERK1/2 and p38 MAP-kinases (p-ERK1/2 and p-p38,
respectively) and for total p38 by western immunoblotting. b-actin was determined as loading control. (D, E) Serum-starved (D) UT-SCC-7 cells (n=2)
and (E) HaCaT cells (n=3) were pretreated with MEK1 inhibitor PD98059 (30 mM) or with p38 inhibitor SB203580 (20 mM) for 1 h and KGF (10 ng/ml)
was added, as indicated. After 24 h, total RNA was harvested and analyzed for MMP-13 mRNA by qPCR. The results were normalized for b-actin mRNA
levels in each sample. (F) UT-SCC-7 cells were treated as in (D) and incubated for 48 h. Equal aliquots of conditioned media were analyzed for MMP-
13 and MMP-1 by western immunoblotting. The level of b-actin in corresponding cell lysstes was determined as loading control. (G) Serum-starved
skin SCC cells (UT-SCC-7, -12A) and HaCaT cells were treated with recombinant KGF (10 ng/ml) for 24 h and equal amounts of total cell lysates were
analyzed for FGFR2 by western immunoblotting. The expression level of b-actin was visualized for estimation of equal loading. (H, I) UT-SCC-7 and
HaCaT cells were treated as in (D, E). After 24 h, total RNA was harvested and analyzed for KGFR mRNA by qPCR. The results were normalized for b-
actin mRNA levels in each sample. *p,0.05, **p,0.01, with independent samples T-test, n=3.
doi:10.1371/journal.pone.0033041.g006
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for KGF in skin SCC cells. MMP-7 is not expressed by
keratinocytes in normal epidermis or in cutaneous wounds, but
it is expressed by tumor cells in cutaneous SCCs [37,38]. MMP-7
is capable of cleaving various ECM components, including
collagen type IV, fibronectin, laminins and proteoglycans
[61,62]. MMP-7 can also regulate cell adhesion and migration
by shedding syndecan-1 and E-cadherin, and promote cell
proliferation by activating HB-EGF from cell surface [63–65].
Thus, downregulation of two transformation-specific MMPs,
MMP-13 and MMP-7, in cutaneous SCC cells by KGF provides
a mechanistic explanation for inhibition of SCC cell invasion.
In conclusion, the results of the present study show that
although most cutaneous SCC cell lines express KGFR, they are
unresponsive to the mitogenic effect of KGF. Furthermore, the
expression of KGFR mRNA was found to correlate negatively
with tumorigenic potential of Ha-ras-transformed HaCaT cells.
KGF reduced invasion capacity of KGFR-positive cutaneous SCC
cells and induced a specific gene expression signature character-
ized by upregulation of a panel of genes associated with tumor
suppression and downregulation of several genes linked to tumor
progression. These results provide evidence for a role for KGF as a
suppressor of malignant phenotype of skin SCC cells. Based on
these findings, we propose that KGF does not promote progression
of cutaneous SCCs, but rather suppresses the malignant
phenotype of SCC cells. However, this beneficial effect of KGF
appears to be compromised in the most aggressive SCC cells due
to downregulation of KGFR expression by a mechanism involving
Figure 7. KGF downregulates MMP-13 and KGFR expression in
Ha-ras-transformed HaCaT cells via ERK1/2. Three Ha-ras-trans-
formed HaCaT cell-derived lines (A5, II4, and RT3) were used. A5 is
benign tumorigenic cell line, II4 forms invasive malignant tumors, and
RT3 cells form metastatic SCCs in vivo.( A) A5, II4, and RT3 cultures were
serum-starved overnight and the cell lysates were analyzed for
phosphorylated ERK1/2 (p-ERK1/2) and total ERK1/2 by western
blotting. b-actin was determined as loading control. (B, C) Serum-
starved A5, II4, and RT3 cells were pre-treated with PD98059 (30 mM) for
1 h and KGF (10 ng/ml) was added. After 24 h, total RNA was extracted
and analyzed for MMP-13 mRNA (B) and KGFR mRNA (C) using qPCR.
The amplification results were normalized for b-actin mRNA levels in
each sample. *p,0.05, **p,0.005, with independent samples T-test,
n=3.
doi:10.1371/journal.pone.0033041.g007
Figure 8. Activation of ERK1/2 downregulates MMP-13 and
KGFR expression in HaCaT cells. Serum-starved HaCaT cells were
infected with control adenovirus RAdLacZ or with adenovirus
RAdMEK1ca harboring constitutively active MEK1 at MOI 500. (A) Cell
lysates were harvested 18 h after infection and analyzed for phosphor-
ylated ERK1/2 (p-ERK1/2) and total ERK1/2 by western blotting. b-actin
was determined as loading control. (B) Total RNA was extracted 48 h
after infection and analyzed for MMP-13 mRNA by qPCR. The
amplification results were normalized for GAPDH mRNA levels in each
sample. (C) Total RNA was extracted 24 h after infection and analyzed
for KGFR by qPCR, as described in (B).
doi:10.1371/journal.pone.0033041.g008
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by eventual loss of KGFR.
Materials and Methods
Ethics statement
All studies involving human patients were approved by the Joint
Ethical Committee of the University of Turku and Turku
University Hospital. Participants gave their informed consent in
writing, and the study was conducted according to declaration of
Helsinki.
Tissue samples
Cutaneous SCC tumor samples (n=6) were collected from
surgically removed primary tumors in Turku University Hospital.
Normal skin samples were obtained from patients undergoing
mammoplasty (n=6) in Turku University Hospital.
Cell cultures
Cutaneous SCC cell lines (n=8) were established at the time
of operation from five primary (UT-SCC-12A, -91, -105, -111
-118) and three metastatic tumors (UT-SCC-7, -59A, -115) in
Turku University Hospital [66]. SCC cells were cultured in
DMEM supplemented with penicillin and streptomycin, 2 mM
L-glutamine, nonessential amino acids and 10% fetal calf serum
(FCS). HaCaT cells [25] and normal human skin fibroblasts
[67] were cultured in DMEM containing antibiotics, L-
glutamine and 10% FCS. Ha-ras-transformed HaCaT cells
(A5, II4, RT3) [44,45] were cultured in DMEM containing
G418 (200 mg/ml), antibiotics, L-glutamine and 10% FCS.
H a C a Tc e l l sa n dH a - ras-transformed HaCaT cells were kindly
provided by Dr. Norbert E. Fusenig, (German Cancer Research
Center, Heidelberg, Germany). Normal epidermal keratinocytes
were established from normal skin of patients undergoing
mammoplasty [66] or purchased from PromoCell Gmbh
(Heidelberg, Germany). Keratinocytes were cultured in Kera-
tinocyte Growth Medium 22 supplemented with Supplement-
Mix (PromoCell).
Cell treatment with recombinant KGF and MAPK
inhibitors
Cutaneous SCC cells or HaCaT cells were serum-starved
overnight and incubated with bacterial recombinant human
KGF (K1757; Sigma-Adrich, St. Luis, MO, USA) for indicated
periods. Keratinocytes were cultured in normal growth medium,
and subsequently treated in a similar manner. Inhibitors of
MEK1/2 (PD98059; Calbiochem, San Diego, CA) and p38
MAPK (SB203580; Calbiochem, San Diego, CA) were added in
30 mMa n d2 0mM concentrations, respectively, one hour prior
to KGF.
Construction of KGF adenovirus and adenoviral gene
delivery
Recombinant replication-deficient adenovirus harboring KGF
cDNA was constructed as described previously [67]. Human KGF
coding cDNA was amplified from dermal fibroblast total RNA and
cloned into pCA3 shuttle vector (Microbix Biosystems, Toronto,
ON, Canada). pCA3 construct and pBHG10 plasmid containing
adenovirus genome were co-transfected into HEK293 cells
(Microbix Biosystems, Toronto, ON, Canada). One KGF-positive
adenovirus clone was selected for the production of high titer
preparation. Human dermal fibroblasts were infected with
RAdKGF or RAdpCA3 control vector in suspension at MOI
200 and plated [67]. The media were changed next day and
harvested 72 h later. KGF concentration in the media were
determined by ELISA, Quantikine Immunoassay, human KGF
(DKG00, R&D Systems, Minneapolis, MN, USA). Recombinant
replication-deficient adenovirus RAdLacZ (kindly provided by
Gavin W. G. Wilkinson) used as a control virus and RAdMEK1ca
harboring constitutively active mutant of MEK1 (kindly provided
by Marco Foschi, University of Florence, Florence, Italy) have
been described before [68,69]. HaCaT cells were cultured in 0.5%
FCS DMEM overnight and infected with adenovirus at multiplic-
ity of infection (MOI) 500 for 6 h.
RNA analysis by RT-PCR and Real-Time Quantitative RT-
PCR
Total RNA was harvested from cells using Qiagen RNeasy kit
(Qiagen GmbH, Hilden, Germany) and 1 mg was DNase-treated
and reverse trancribed to cDNA using random oligohexamer
primers. For KGFR, cDNA was ampified using PCR-primers
(frw59-CACTCGGGGATAAATAGTTC-39 and rev59-CTTG-
CTGTTTTGGCAGGACA-39) designed to recognize the specific
IIIb-type exon of FGFR2-transcripts [3] generating in a nucleotide
fragment of 148 bp. The forward primer 59-CCCCTTCATT-
GACCTCAACT-39 and reverse primer 59-ATGACCTTGCC-
CACAGCCTT-39 were used to amplify a 550 bp fragment of
glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) transcript
as loading control. Equal aliquots of each reaction were run in
agarose gel containing ethidiumbromide to visualize DNA
fragments.
Quantitative analysis of mRNA expression was performed from
3 or 4 laboratory replicates of untreated and KGF-treated (10 ng/
ml, 24 h) cells [66]. 4 ng aliquots of cDNA were used in each
reaction run in three experimental replicates. All mRNAs were
normalized against amplification of house-keeping genes b-actin
or GAPDH. Standard deviation of the experimental replicates in
one run was #3% of the Ct mean for each sample. Tissue RNAs
were extracted and processed for qPCR and run in two
experimental replicates, as described previously [66]. Sequences
for specific primers and probe for MMP-13 have been published
[66]. In addition, the sequences of the gene specific primers and
probes used are presented in Table 3.
Microarray analysis of gene expression profiling
Genome wide gene expression profiling was performed at The
Finnish DNA Microarray and Sequencing Centre, Turku,
Finland. 100 ng of total RNA was processed for hybridization to
Affymetrix Human Gene 1.0 ST Array [70]. CEL-files were
extracted with GCOS Manager 1.4. The data quality was checked
using Affymetrix Expression Console
TM software, and for probe
set level intensity comparisons, Expression Console
TM and RMA
algorithm were used to generate CHP array result files from CEL-
files. All microarray data is MIAME compliant and has been
deposited in the public database GEO (Gene Expression
Omnibus, NCBI; accession number GSE34652). The genes with
more than 22.0 fold (#50%) or 1.5 fold (150%#) changes in
expression level between the KGF-treated sample and control
sample were considered to be differently regulated. The data
presented are ratios of hybridization signal between treated and
untreated control cell samples. Only the genes with the signal
above the median of the signal intensity distribution present in at
least one sample were included. Ingenuity Pathway Analysis
(Ingenuity Systems, www.ingenuity.com) was employed to visual-
ize molecular interaction networks induced by KGF in skin SCC
cell lines.
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Equal aliquots of cell culture media or cell lysates were analyzed
by Western immunoblotting, as previously described [66].
Following antibodies were used: mouse monoclonal antibodies
against human MMP-13 (IM64L; Millipore, Billerica, MA) and
b-actin (A1978; Sigma-Adrich, St. Louis, MO, USA); rabbit
polyclonal antibodies against human FGFR2 (F0300, Sigma-
Adrich, St. Louis, MO, USA), MMP-2 (AB809; Chemicon
International Inc., Temecula, CA), MMP-1 (AB8105; Millipore,
Billerica, MA), total and phosphorylated p38 (#9212 and #9211,
respectively), and ERK1/2 (#9102 and #9101, respectively), and
phosphorylated Creb (#9191) (Cell Signaling Technology,
Beverly, MA) and goat polyclonal anti-human FGF-7 (C-terminal
peptide) (C-19) (sc-1365, Santa Cruz Biotechnology, Inc., Santa
Cruz CA).
Cell Invasion Assay
Cell culture chambers with 8 mm pore size (BD Falcon, Franklin
Lakes, NJ) were pre-coated with 1 mm thick layer of neutralized
bovine collagen (2.1 mg/ml, PureCol, Advanced BioMatrix,
Tucson, AZ). Cells were serum starved and treated with KGF
(10 ng/ml) for 24 h, suspended (3610
5 cells) in 300 ml DMEM
containing 0.1% BSA and applied on top of gels. DMEM
containing 10% FCS was used as chemoattractant in the lower
chamber. The upper and the lower chambers contained KGF.
After 48 h, the gels including non-invaded cells were removed
inside the upper chamber and the cells that had migrated through
the pores to the other side of the chamber bottom, were stained
with Hoechst 33342 and counted in comparable areas [66].
Cell proliferation assays
DNA-synthesis was measured with colorimetric immunoassay
quantifying the incorporation of 5-bromo-2-deoxyuridine (BrdU)
into DNA, as described previously [71]. BrdU was added in
culture media 2 h after starting the growth factor stimulation and
incubated for 18 h. For cell stimulation by conditioned cell culture
medium, BrdU was added 18 h after starting the stimulation and
incubated for 8 h.
Relative number of viable cells in culture was assayed using
colorimetric assay quantifying metabolism of WST-1 reagent
according to manufacturer’s instructions (Roche Applied Science,
Mannheim, Germany). Cells were serum starved overnight and
incubated with rKGF for 48 h before addition of WST-1.
Statistical analysis
Data obtained from qPCR and invasion assays were analyzed
by 2-sided two independent samples T-test utilizing Levene’s test
for equality of variances. Data from proliferation assays comparing
control to each treatment were analyzed using 2-sided two
independent samples Mann-Whitney test. All tests were conducted
with SPSS 16.0 software (SPSS Inc.). P-values,0.05 were
considered statistically significant. All the experiments were
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